3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Nivolumab
3
ulixertinib
2
binimetinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
selpercatinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
durvalumab
×
30 days
×
Clear all
No trials found.